Relay Therapeutics (RLAY) Stock Forecast, Price Target & Predictions
RLAY Stock Forecast
Relay Therapeutics stock forecast is as follows: an average price target of $19.40 (represents a 231.62% upside from RLAY’s last price of $5.85) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
RLAY Price Target
The average price target for Relay Therapeutics (RLAY) is $19.40 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $16.00. This represents a potential 231.62% upside from RLAY's last price of $5.85.
RLAY Analyst Ratings
According to 9 Wall Street analysts, Relay Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RLAY stock is 1 'Strong Buy' (11.11%), 7 'Buy' (77.78%), 1 'Hold' (11.11%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Relay Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Robert Burns | H.C. Wainwright | $19.00 | $7.60 | 150.00% | 224.79% |
| Sep 10, 2024 | Akash Tewari | Jefferies | $16.00 | $9.51 | 68.24% | 173.50% |
| Sep 09, 2024 | Peter Lawson | Barclays | $17.00 | $9.51 | 78.76% | 190.60% |
| Sep 04, 2024 | Jason Gerberry | Bank of America Securities | $20.00 | $6.41 | 212.01% | 241.88% |
| May 10, 2024 | Peter Lawson | Barclays | $15.00 | $6.68 | 124.66% | 156.41% |
| May 06, 2024 | Matt Biegler | Oppenheimer | $25.00 | $7.04 | 255.11% | 327.35% |
| Apr 20, 2023 | Akash Tewari | Jefferies | $12.50 | $12.35 | 1.21% | 113.68% |
| Feb 03, 2023 | - | Oppenheimer | $33.00 | $22.76 | 44.99% | 464.10% |
| Sep 30, 2022 | Peter Lawson | Barclays | $23.00 | $23.14 | -0.61% | 293.16% |
The latest Relay Therapeutics stock forecast, released on Sep 16, 2024 by Robert Burns from H.C. Wainwright, set a price target of $19.00, which represents a 150.00% increase from the stock price at the time of the forecast ($7.60), and a 224.79% increase from RLAY last price ($5.85).
Relay Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 6 |
| Avg Price Target | - | $18.00 | $18.67 |
| Last Closing Price | $5.85 | $5.85 | $5.85 |
| Upside/Downside | -100.00% | 207.69% | 219.15% |
In the current month, the average price target of Relay Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Relay Therapeutics's last price of $5.85. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 09, 2024 | Oppenheimer | Buy | Perform | Downgrade |
| Sep 09, 2024 | Barclays | Overweight | Overweight | Hold |
| Sep 04, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Aug 07, 2024 | Oppenheimer | Buy | Buy | Hold |
| Aug 07, 2024 | JMP Securities | Underperform | Underperform | Hold |
| Jul 17, 2024 | JMP Securities | Underperform | Underperform | Hold |
| Jul 17, 2024 | Oppenheimer | Market Outperform | Market Outperform | Hold |
| Jun 07, 2024 | Cowen & Co. | Buy | Buy | Hold |
Relay Therapeutics's last stock rating was published by H.C. Wainwright on Oct 14, 2024. The company gave RLAY a "Buy" rating, the same as its previous rate.
Relay Therapeutics Financial Forecast
Relay Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $25.20M | $119.00K | $226.00K | $253.00K | $344.00K | $365.00K | $419.00K | $567.00K | $666.00K | $844.00K | $952.00K | $82.65M |
| Avg Forecast | $40.00K | $40.00K | $50.00K | $50.00K | $88.89K | $88.89K | $88.89K | $120.00K | $581.82K | $374.55K | $741.67K | $128.00K | $271.43K | $1.80M | $2.08M | $166.67K | $3.84M | $107.14K | $6.67M | $3.39M | $36.67M |
| High Forecast | $40.00K | $40.00K | $50.00K | $50.00K | $88.89K | $126.98K | $88.94K | $121.50K | $1.08M | $377.04K | $741.67K | $128.00K | $271.43K | $1.80M | $2.08M | $166.67K | $3.84M | $107.14K | $6.67M | $3.39M | $36.67M |
| Low Forecast | $40.00K | $40.00K | $50.00K | $50.00K | $88.89K | $50.79K | $88.83K | $118.50K | $215.49K | $372.05K | $741.67K | $128.00K | $271.43K | $1.80M | $2.08M | $166.67K | $3.84M | $107.14K | $6.67M | $3.39M | $36.67M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 3 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | 67.29% | 0.16% | 1.77% | 0.93% | 0.19% | 0.18% | 2.51% | 0.15% | 6.22% | 0.13% | 0.28% | 2.25% |
Relay Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $581.82K, with a low forecast of $215.49K, and a high forecast of $1.08M. RLAY's average Quarter revenue forecast represents a -97.69% decrease compared to the company's last Quarter revenue of $25.20M (Sep 23).
Relay Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 3 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-73.58M | $-106.05M | $-101.18M | $-93.94M | $-78.33M | $-76.45M | $-70.94M | $-66.42M | $-59.82M | $-192.44M | $-41.27M | $36.19M |
| Avg Forecast | $-21.06K | $-21.06K | $-26.32K | $-26.32K | $-46.79K | $-46.79K | $-46.79K | $-57.04M | $-306.28K | $-197.17K | $-390.43K | $-61.00M | $-57.82M | $-947.56K | $-1.10M | $-65.24M | $-2.02M | $-56.40K | $-3.51M | $-42.12M | $-19.30M |
| High Forecast | $-21.06K | $-21.06K | $-26.32K | $-26.32K | $-46.79K | $-26.74K | $-46.76K | $-45.63M | $-113.44K | $-195.85K | $-390.43K | $-48.80M | $-46.26M | $-947.56K | $-1.10M | $-52.20M | $-2.02M | $-56.40K | $-3.51M | $-33.70M | $-19.30M |
| Low Forecast | $-21.06K | $-21.06K | $-26.32K | $-26.32K | $-46.79K | $-66.85K | $-46.82K | $-68.45M | $-567.19K | $-198.48K | $-390.43K | $-73.20M | $-69.39M | $-947.56K | $-1.10M | $-78.29M | $-2.02M | $-56.40K | $-3.51M | $-50.55M | $-19.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | 373.17% | 271.62% | 1.66% | 1.62% | 82.67% | 69.71% | 1.09% | 32.86% | 1060.62% | 54.83% | 0.98% | -1.87% |
6 analysts predict RLAY's average Quarter EBITDA for Mar 21 to be $-42.12M, with a high of $-33.70M and a low of $-50.55M. This is -216.41% lower than Relay Therapeutics's previous annual EBITDA (Dec 20) of $36.19M.
Relay Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 3 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | $-65.73M | $-98.50M | $-87.30M | $-43.31M | $-87.26M | $-75.16M | $-51.48M | $-67.46M | $-60.83M | $-193.40M | $-42.18M | $35.28M |
| Avg Forecast | $-106.04M | $-104.71M | $-103.60M | $-99.24M | $-99.59M | $-102.53M | $-97.32M | $-58.62M | $-95.39M | $-109.58M | $-108.31M | $-62.69M | $-58.72M | $-93.71M | $-83.30M | $-67.05M | $-74.24M | $-81.29M | $-59.58M | $-43.06M | $22.36M |
| High Forecast | $-106.04M | $-104.71M | $-103.60M | $-99.24M | $-99.59M | $-93.21M | $-97.32M | $-46.89M | $-87.86M | $-88.45M | $-108.31M | $-50.15M | $-46.98M | $-93.71M | $-83.30M | $-53.64M | $-74.24M | $-81.29M | $-59.58M | $-34.45M | $22.36M |
| Low Forecast | $-106.04M | $-104.71M | $-103.60M | $-99.24M | $-99.59M | $-109.18M | $-97.32M | $-70.34M | $-99.15M | $-118.82M | $-108.31M | $-75.23M | $-70.47M | $-93.71M | $-83.30M | $-80.46M | $-74.24M | $-81.29M | $-59.58M | $-51.68M | $22.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.60% | 0.91% | 1.39% | 0.74% | 0.93% | 0.90% | 0.77% | 0.91% | 0.75% | 3.25% | 0.98% | 1.58% |
Relay Therapeutics's average Quarter net income forecast for Mar 21 is $-43.06M, with a range of $-51.68M to $-34.45M. RLAY's average Quarter net income forecast represents a -222.07% decrease compared to the company's last Quarter net income of $35.28M (Dec 20).
Relay Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 3 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | $18.48M | $20.12M | $19.58M | $16.37M | $16.07M | $17.46M | $16.07M | $15.55M | $14.68M | $14.42M | $12.73M | $15.54M |
| Avg Forecast | $568.97K | $568.97K | $711.22K | $711.22K | $1.26M | $1.26M | $1.26M | $1.71M | $8.28M | $5.33M | $10.55M | $1.82M | $3.86M | $25.60M | $29.63M | $2.37M | $54.62M | $1.52M | $94.83M | $48.23M | $521.56M |
| High Forecast | $568.97K | $568.97K | $711.22K | $711.22K | $1.26M | $1.81M | $1.27M | $1.73M | $15.33M | $5.36M | $10.55M | $1.82M | $3.86M | $25.60M | $29.63M | $2.37M | $54.62M | $1.52M | $94.83M | $48.23M | $521.56M |
| Low Forecast | $568.97K | $568.97K | $711.22K | $711.22K | $1.26M | $722.50K | $1.26M | $1.69M | $3.07M | $5.29M | $10.55M | $1.82M | $3.86M | $25.60M | $29.63M | $2.37M | $54.62M | $1.52M | $94.83M | $48.23M | $521.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.47% | 1.91% | 10.75% | 4.24% | 0.63% | 0.59% | 6.78% | 0.28% | 9.63% | 0.15% | 0.26% | 0.03% |
Relay Therapeutics's average Quarter SG&A projection for Dec 23 is $8.28M, based on 3 Wall Street analysts, with a range of $3.07M to $15.33M. The forecast indicates a -55.23% fall compared to RLAY last annual SG&A of $18.48M (Sep 23).
Relay Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 3 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.72 | $-0.36 | $-0.79 | $-0.69 | $-0.48 | $-0.66 | $-0.66 | $-2.10 | $-0.47 | $0.50 |
| Avg Forecast | $-0.80 | $-0.79 | $-0.78 | $-0.75 | $-0.75 | $-0.77 | $-0.73 | $-0.73 | $-0.72 | $-0.82 | $-0.82 | $-0.69 | $-0.70 | $-0.71 | $-0.63 | $-0.62 | $-0.56 | $-0.61 | $-0.45 | $-0.49 | $0.17 |
| High Forecast | $-0.80 | $-0.79 | $-0.78 | $-0.75 | $-0.75 | $-0.70 | $-0.73 | $-0.73 | $-0.66 | $-0.67 | $-0.82 | $-0.69 | $-0.70 | $-0.71 | $-0.63 | $-0.62 | $-0.56 | $-0.61 | $-0.45 | $-0.49 | $0.17 |
| Low Forecast | $-0.80 | $-0.79 | $-0.78 | $-0.75 | $-0.75 | $-0.82 | $-0.73 | $-0.73 | $-0.75 | $-0.89 | $-0.82 | $-0.69 | $-0.70 | $-0.71 | $-0.63 | $-0.62 | $-0.56 | $-0.61 | $-0.45 | $-0.49 | $0.17 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 1.04% | 0.51% | 1.12% | 1.10% | 0.78% | 1.18% | 1.08% | 4.68% | 0.97% | 2.94% |
According to 6 Wall Street analysts, Relay Therapeutics's projected average Quarter EPS for Mar 21 is $-0.49, with a low estimate of $-0.49 and a high estimate of $-0.49. This represents a -198.10% decrease compared to RLAY previous annual EPS of $0.50 (Dec 20).
Relay Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
| RLAY | Relay Therapeutics | $5.85 | $19.40 | 231.62% | Buy |
| PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
| ARVN | Arvinas | $26.80 | $71.82 | 167.99% | Buy |
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| FHTX | Foghorn Therapeutics | $8.24 | $16.33 | 98.18% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| NRIX | Nurix Therapeutics | $25.04 | $32.20 | 28.59% | Buy |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
RLAY Forecast FAQ
Is Relay Therapeutics a good buy?
Yes, according to 9 Wall Street analysts, Relay Therapeutics (RLAY) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 7 'Buy' recommendations, accounting for 88.89% of RLAY's total ratings.
What is RLAY's price target?
Relay Therapeutics (RLAY) average price target is $19.4 with a range of $16 to $25, implying a 231.62% from its last price of $5.85. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Relay Therapeutics stock go up soon?
According to Wall Street analysts' prediction for RLAY stock, the company can go up by 231.62% (from the last price of $5.85 to the average price target of $19.4), up by 327.35% based on the highest stock price target, and up by 173.50% based on the lowest stock price target.
Can Relay Therapeutics stock reach $9?
RLAY's average twelve months analyst stock price target of $19.4 supports the claim that Relay Therapeutics can reach $9 in the near future.
What are Relay Therapeutics's analysts' financial forecasts?
Relay Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $386.67K (high $426.32K, low $347.02K), average EBITDA is $-57.178M (high $-45.751M, low $-68.606M), average net income is $-358M (high $-337M, low $-376M), average SG&A $5.5M (high $6.06M, low $4.94M), and average EPS is $-2.981 (high $-2.911, low $-3.031). RLAY's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $180K (high $180K, low $180K), average EBITDA is $-94.754K (high $-94.754K, low $-94.754K), average net income is $-414M (high $-414M, low $-414M), average SG&A $2.56M (high $2.56M, low $2.56M), and average EPS is $-3.114 (high $-3.114, low $-3.114).
Did the RLAY's actual financial results beat the analysts' financial forecasts?
Based on Relay Therapeutics's last annual report (Dec 2022), the company's revenue was $1.38M, which missed the average analysts forecast of $4.32M by -68.04%. Apple's EBITDA was $-323M, beating the average prediction of $-125M by 157.88%. The company's net income was $-254M, missing the average estimation of $-303M by -16.03%. Apple's SG&A was $65.98M, beating the average forecast of $61.47M by 7.33%. Lastly, the company's EPS was $-2.27, missing the average prediction of $-2.653 by -14.44%. In terms of the last quarterly report (Sep 2023), Relay Therapeutics's revenue was $25.2M, beating the average analysts' forecast of $374.54K by 6628.70%. The company's EBITDA was $-73.577M, beating the average prediction of $-197K by 37216.72%. Relay Therapeutics's net income was $-65.734M, missing the average estimation of $-110M by -40.01%. The company's SG&A was $18.48M, beating the average forecast of $5.33M by 246.96%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.825 by -99.94%